IceCure Medical (NASDAQ: ICCM) has announced positive topline results from the ICESECRET clinical study of its ProSense Cryoablation System for the treatment of small renal masses in kidney cancer patients. Detailed...
Brookline Capital Markets initiated coverage of IceCure Medical (NASDAQ:ICCM) with a “buy” rating and price target of $5.65. The stock closed at $2.59 on Feb. 1. IceCure is a commercial-stage medical device company...
Alliance Global Partners launched coverage of IceCure Medical (NASDAQ:ICCM) with a “buy” rating and price target of $14.50. The stock closed at $8.61 on Sept. 21. IceCure has developed and markets the IceCure family of...